Loading
A study of up to 50,000 older Americans on Medicare that gives them the Galleri test and compares how many cancers are found at stage IV.
REACH (NCT05673018) is a non-randomised interventional study sponsored by GRAIL, Inc. Its registry primary outcome is the incidence of stage IV cancers; it assesses real-world clinical impact, safety and test performance.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 50,000 participants, a start on 12 July 2024 and primary completion expected in September 2030.
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/